FDA Approval Sought for Extended Pembrolizumab Dosing Schedule for Select Indications

Source: OncLive, July 2019

The FDA has accepted 6 supplemental biologics license applications (sBLAs) for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.1 The new dosage would be applicable for the PD-1 inhibitor’s following indications: melanoma, Merkel cell carcinoma, gastric cancer, hepatocellular carcinoma, classical Hodgkin lymphoma, and primary mediastinal large B-cell lymphoma.

For the sBLAs, the dosing schedule would be updated in the following indications:

 

read the original full article

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder